Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Published by fortebiorx.com. Opens in a new tab.
More news
- Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
- Ocean Capital Acquisition Corporation Prices $100 Million Initial Public Offering
- Aeon Acquisition I Corp. Announces Pricing of $125 Million Initial Public Offering
- Perimeter Medical Imaging AI Closes Life Offering